Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced that it has received approval from the Ministry of Health and Welfare of Taiwan to conduct a Phase I clinical study of its therapeutic candidate STP705 for advanced liver cancer.
Drug Profile
STP705 is a siRNA (small interfering RNA) therapeutic that leverages a dual-targeted inhibitory approach and polypeptide nanoparticle (PNP)-enhanced delivery to directly suppress TGF-β1 and COX-2 gene expression. The product has been granted orphan drug designations (ODD) for use in cholangiocarcinoma and primary sclerosing cholangitis. It is currently in clinical trials for cholangiocarcinoma, non-melanoma skin cancer, skin squamous cell carcinoma in situ, and hypertrophic scarring.-Fineline Info & Tech
